Latest & greatest articles for metformin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metformin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metformin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metformin

81. The effect of ranolazine on glycemic control in patients with type 2 diabetes treated with either glimepiride or metformin

The effect of ranolazine on glycemic control in patients with type 2 diabetes treated with either glimepiride or metformin 26749407 2016 04 13 2017 01 06 2017 01 07 1463-1326 18 5 2016 May Diabetes, obesity & metabolism Diabetes Obes Metab Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin. 463-74 10.1111/dom.12629 To report the results of two phase III trials assessing the efficacy of ranolazine for glycaemic control (...) in patients with type 2 diabetes on metformin or glimepiride background therapy. In two double-blind trials we randomized 431 and 442 patients with type 2 diabetes to ranolazine 1000 mg twice daily versus placebo added to either glimepiride (glimepiride add-on study) or metformin background therapy (metformin add-on study). Patients receiving ranolazine added to metformin had their metformin dose halved (with the addition of a metformin-matched placebo) relative to the placebo group to correct

EvidenceUpdates2016

82. Canagliflozin and metformin hydrochloride (TBC)

Canagliflozin and metformin hydrochloride (TBC) Canagliflozin and metformin hydrochloride | CADTH.ca Find the information you need Canagliflozin and metformin hydrochloride Canagliflozin and metformin hydrochloride Last Updated: Result type: Reports Project Number: SR0480-000 Product Line: Generic Name: Canagliflozin and metformin hydrochloride Brand Name: Invokamet Manufacturer: Janssen Inc. Indications: Diabetes mellitus, type 2 Submission Type: New Project Status: Active Date Recommendation

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2016

83. Could Metformin be the First Anti-Aging Drug?

Could Metformin be the First Anti-Aging Drug? Could Metformin be the First Anti-Aging Drug? | Clinical Correlations Could Metformin be the First Anti-Aging Drug? February 11, 2016 By Amy Shen Tang, MD P eer Reviewed “I would pay you if you took it away from me. I’d try to buy it back,” said Irving Kahn, the late Wall Street [1]. Mr. Kahn, who founded Kahn Brothers Group, Inc. with his sons more than 40 years ago, took an active role as chair of his company until his passing last winter (...) at the Institute for Aging Research are looking to make a cheap, generic, widely used drug—metformin—the first to be Food and Drug Association (FDA)-approved for the indication of aging. Metformin is an oral biguanide antidiabetic medication that has been used for over 50 years. It is commonly prescribed as a first-line treatment for type 2 diabetes mellitus and often in combination with other antidiabetic medications including insulin. Metformin reduces blood glucose levels by preventing glucose production

Clinical Correlations2016

84. Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naive Type 2 Diabetes

Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naive Type 2 Diabetes 26786577 2016 02 24 2016 12 13 2016 12 30 1935-5548 39 3 2016 Mar Diabetes care Diabetes Care Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes. 353-62 10.2337/dc15-1736 This study assessed the efficacy/safety of canagliflozin (CANA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor (...) , plus metformin extended-release (MET) initial therapy in drug-naïve type 2 diabetes. This 26-week, double-blind, phase 3 study randomized 1,186 patients to CANA 100 mg (CANA100)/MET, CANA 300 mg (CANA300)/MET, CANA100, CANA300, or MET. Primary end point was change in HbA(1c) at week 26 for combinations versus monotherapies. Secondary end points included noninferiority in HbA(1c) lowering with CANA monotherapy versus MET; changes in fasting plasma glucose, body weight, and blood

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

85. dapagliflozin/metformin hydrochloride (XigDuo)

dapagliflozin/metformin hydrochloride (XigDuo) dapagliflozin/metformin hydrochloride | CADTH.ca Find the information you need dapagliflozin/metformin hydrochloride dapagliflozin/metformin hydrochloride Last Updated: Result type: Reports Project Number: SR0468-000 Product Line: Generic Name: dapagliflozin/metformin hydrochloride Brand Name: XigDuo Manufacturer: AstraZeneca Canada Inc. Indications: Diabetes Mellitus, Type 2 Submission Type: New Project Status: Active Date Recommendation Issued

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2016

86. Observational study: Prescribing of metformin based on estimated GFR rather than serum creatinine expands the eligible population and is likely safe

Observational study: Prescribing of metformin based on estimated GFR rather than serum creatinine expands the eligible population and is likely safe Prescribing of metformin based on estimated GFR rather than serum creatinine expands the eligible population and is likely safe | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Prescribing of metformin based on estimated GFR rather than serum creatinine expands the eligible population and is likely safe Article Text Therapeutics/Prevention Observational study Prescribing of metformin based on estimated GFR

Evidence-Based Medicine (Requires free registration)2016

87. Randomised controlled trial: Metformin reduces weight gain in overweight/obese adolescents with type 1 diabetes

Randomised controlled trial: Metformin reduces weight gain in overweight/obese adolescents with type 1 diabetes Metformin reduces weight gain in overweight/obese adolescents with type 1 diabetes | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Metformin reduces weight gain in overweight/obese adolescents with type 1 diabetes Article Text Therapeutics/Prevention Randomised controlled trial Metformin reduces weight gain in overweight/obese adolescents with type 1 diabetes Arya M Sharma Statistics from Altmetric.com No Altmetric data available for this article

Evidence-Based Medicine (Requires free registration)2016

88. Saxagliptin + saxagliptin/metformin: Addendum to Commission A16-42 + A16-43

Saxagliptin + saxagliptin/metformin: Addendum to Commission A16-42 + A16-43 Saxagliptin und Saxagliptin/Metformin (Diabetes mellitus Typ 2): Addendum zu den Aufträgen A16-42 und A16-43; Auftrag A16-71 [Saxagliptin + saxagliptin/metformin: Addendum to Commission A16-42 + A16-43] Saxagliptin und Saxagliptin/Metformin (Diabetes mellitus Typ 2): Addendum zu den Aufträgen A16-42 und A16-43; Auftrag A16-71 [Saxagliptin + saxagliptin/metformin: Addendum to Commission A16-42 + A16-43] Institut für (...) Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Saxagliptin und Saxagliptin/Metformin (Diabetes mellitus Typ 2): Addendum zu den Aufträgen A16-42 und A16-43; Auftrag A16-71. [Saxagliptin + saxagliptin/metformin: Addendum

Health Technology Assessment (HTA) Database.2016

89. Systematic review with meta analysis: Existing evidence is insufficient to justify metformin or other agents as first-line therapy for type 2 diabetes

Systematic review with meta analysis: Existing evidence is insufficient to justify metformin or other agents as first-line therapy for type 2 diabetes Existing evidence is insufficient to justify metformin or other agents as first-line therapy for type 2 diabetes | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Existing evidence is insufficient to justify metformin or other agents as first-line therapy for type 2 diabetes Article Text Therapeutics/Prevention Systematic review with meta analysis Existing evidence is insufficient to justify metformin

Evidence-Based Medicine (Requires free registration)2016

90. Systematic review with meta-analysis: Most add-on therapies to metformin have similar effects on HbA1c

Systematic review with meta-analysis: Most add-on therapies to metformin have similar effects on HbA1c Most add-on therapies to metformin have similar effects on HbA1c | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu (...) Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Most add-on therapies to metformin have similar effects on HbA1c Article Text Therapeutics/Prevention Systematic review with meta-analysis Most add-on therapies to metformin have similar effects on HbA1c Thomas Karagiannis 1 , Eleni Bekiari 1 , 2 Statistics from Altmetric.com Commentary on: Maruthur NM , Tseng E , Hutfless S , et al

Evidence-Based Medicine (Requires free registration)2016

91. Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.

Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. 26624824 2015 12 02 2016 01 04 2017 04 27 1538-3598 314 21 2015 Dec 01 JAMA JAMA Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. 2241-50 10.1001/jama.2015.16174 Previous studies assessing the effect of metformin on glycemic control in adolescents with type (...) 1 diabetes have produced inconclusive results. To assess the efficacy and safety of metformin as an adjunct to insulin in treating overweight adolescents with type 1 diabetes. Multicenter (26 pediatric endocrinology clinics), double-blind, placebo-controlled randomized clinical trial involving 140 adolescents aged 12.1 to 19.6 years (mean [SD] 15.3 [1.7] years) with mean type 1 diabetes duration 7.0 (3.3) years, mean body mass index (BMI) 94th (4) percentile, mean total daily insulin 1.1 (0.2) U/kg, and mean

JAMA2015 Full Text: Link to full Text with Trip Pro

92. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study

Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study 25970814 2015 10 19 2016 08 02 2015 10 19 1464-5491 32 11 2015 Nov Diabetic medicine : a journal of the British Diabetic Association Diabet. Med. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study. 1460-9 10.1111/dme.12800 To compare (...) the cardiovascular risks associated with second-line oral antidiabetic agents added to initial metformin therapy in a large nationwide observational study. We conducted a nationwide retrospective cohort study using the Taiwan National Health Insurance database. A total of 36 118 users of different add-on oral antidiabetic agents (sulphonylureas, glinides, pioglitazone, α-glucosidase inhibitors and dipeptidyl peptidase-4 inhibitors) after initial metformin therapy were included in the analysis. The reference

EvidenceUpdates2015

93. Is It Time to Reconsider Who Should Get Metformin?

Is It Time to Reconsider Who Should Get Metformin? Is It Time to Reconsider Who Should Get Metformin? | Clinical Correlations Is It Time to Reconsider Who Should Get Metformin? December 11, 2015 By Lauren Strazzulla Current FDA guidelines for the use of metformin stipulate that it not be prescribed to those with an elevated creatinine (at or above 1.5 mg/dL for men and 1.4 mg/dL for women). It is also contraindicated in patients with heart failure requiring pharmacologic treatment, and people (...) over age 80, unless their creatinine demonstrates that renal function is not reduced. These guidelines are in place to prevent lactic acidosis, an understandably feared complication of metformin. However, metformin is, by consensus, the initial drug of choice in type 2 diabetes and may prevent or delay the disease in people with pre-diabetes. Metformin is used successfully with less restriction throughout Europe, where it is considered acceptable to prescribe as long as the patient’s

Clinical Correlations2015

94. Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes

Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes 26212528 2015 10 21 2016 07 28 2015 10 21 1463-1326 17 11 2015 Nov Diabetes, obesity & metabolism Diabetes Obes Metab Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes. 1075-84 10.1111/dom.12543 To evaluate the safety and efficacy of dapagliflozin as add-on therapy to metformin plus sulphonylurea over 52 weeks (...) . Patients with type 2 diabetes mellitus (T2DM) using sulphonylurea and metformin received dapagliflozin 10 mg/day or placebo added to therapy for 52 weeks (24-week randomized, double-blind period plus 28-week double-blind extension). A total of 219 patients were randomized 1 : 1 to dapagliflozin or placebo. Over 52 weeks, glycated haemoglobin (HbA1c) and fasting plasma glucose levels showed greater improvement from baseline with dapagliflozin (-0.8% and -1.5 mmol/l) than with placebo (-0.1% and 0.6 mmol

EvidenceUpdates2015

95. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial 26179619 2015 10 21 2016 07 28 2017 02 20 1463-1326 17 11 2015 Nov Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. 1056-64 (...) 10.1111/dom.12539 To confirm the superiority, compared with placebo, of adding liraglutide to pre-existing basal insulin analogue ± metformin in adults with inadequately controlled type 2 diabetes [glycated haemoglobin (HbA1c) 7.0-10.0% (53-86 mmol/mol)]. In this 26-week, double-blind, parallel-group study, conducted in clinics or hospitals, 451 subjects were randomized 1 : 1 to once-daily liraglutide 1.8 mg (dose escalated from 0.6 and 1.2 mg/day, respectively, for 1 week each; n = 226) or placebo (n

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

96. Empagliflozin/metformin (Synjardy) - type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control

Empagliflozin/metformin (Synjardy) - type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control Published 12 October 2015 Product Update: empagliflozin plus metformin 5mg/85mg, 5mg/1000mg, 12.5mg/850mg, 12.5mg/1000mg film-coated tablets (Synjardy ® ) SMC No. (1092/15) Boehringer Ingelheim Ltd. 4 September 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (...) (ADTCs) on its use in Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission empagliflozin/metformin (Synjardy ® ) is accepted for restricted use within NHS Scotland. Indication under review: in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control; • in patients inadequately controlled on their maximally tolerated dose of metformin alone • in patients inadequately controlled with metformin

Scottish Medicines Consortium2015

97. Clinical Review: Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin and a Sulfonylurea

Clinical Review: Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin and a Sulfonylurea Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin and a Sulfonylurea | CADTH.ca Find the information you need Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin and a Sulfonylurea Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin (...) and a Sulfonylurea Published on: August 16, 2010 Product Line: Therapeutic Review Result type: Report Tags diabetes mellitus, diabetes mellitus, type 2, type 2 diabetes mellitus, diabetes mellitus, type ii, metformin, sulfonylurea compounds, diabetes, Third-Line Therapy for Patients with Type 2, Diabetes Inadequately Controlled with, Metformin and a Sulfonylurea Files Therapeutic Review Recommendation Report August 2010 Therapeutic Review Economic Evaluation August 2010 Therapeutic Review Clinical Review August

CADTH - Therapeutic Review2015

98. Economic Evaluation: Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin and Sulfonylurea Combination Therapy

Economic Evaluation: Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin and Sulfonylurea Combination Therapy Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin and a Sulfonylurea | CADTH.ca Find the information you need Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin and a Sulfonylurea Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled (...) with Metformin and a Sulfonylurea Published on: August 16, 2010 Product Line: Therapeutic Review Result type: Report Tags diabetes mellitus, diabetes mellitus, type 2, type 2 diabetes mellitus, diabetes mellitus, type ii, metformin, sulfonylurea compounds, diabetes, Third-Line Therapy for Patients with Type 2, Diabetes Inadequately Controlled with, Metformin and a Sulfonylurea Files Therapeutic Review Recommendation Report August 2010 Therapeutic Review Economic Evaluation August 2010 Therapeutic Review

CADTH - Therapeutic Review2015

99. Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)

Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2) 26089386 2015 11 25 2016 06 27 2015 11 25 1935-5548 38 12 2015 Dec Diabetes care Diabetes Care Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). 2241-9 10.2337/dc14-1625 This study compared the efficacy and safety of once-weekly dulaglutide, a glucagon-like (...) peptide-1 receptor agonist, with daily insulin glargine, both combined with maximally tolerated doses of metformin and glimepiride in patients with type 2 diabetes. The primary objective was noninferiority of dulaglutide 1.5 mg to glargine in the HbA1c change from baseline at 52 weeks. In this 78-week, open-label study, 810 patients were randomized to dulaglutide 1.5 mg, dulaglutide 0.75 mg, or glargine. The baseline mean ± SD HbA1c was 8.1 ± 1.0% (65.5 ± 10.8 mmol/mol). The least squares mean ± SE

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

100. Linagliptin + metformin (Jentadueto) - type 2 diabetes mellitus

Linagliptin + metformin (Jentadueto) - type 2 diabetes mellitus Published 08 June 2015 Product Update linagliptin 2.5mg plus metformin 850mg and linagliptin 2.5mg plus metformin 1000mg film-coated tablets (Jentadueto ® ) SMC No. (1057/15) Boehringer Ingelheim 08 May 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows (...) : ADVICE: following an abbreviated submission linagliptin plus metformin combination tablets (Jentadueto ® ) is accepted for restricted use within NHS Scotland. Indication under review: for the treatment of adult patients with type 2 diabetes mellitus in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control when insulin and metformin alone do not provide adequate glycaemic control. SMC restriction: to use in patients for whom

Scottish Medicines Consortium2015